|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2012. CA Cancer J Clin.
62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He Y, Zheng R, Li D, Zeng H, Zhang S and
Chen W: Pancreatic cancer incidence and mortality patterns in
China, 2011. Chin J Cancer Res. 27:29–37. 2015.PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wei X, Wang W, Wang L, Zhang Y, Zhang X,
Chen M, Wang F, Yu J, Ma Y and Sun G: MicroRNA-21 induces
5-fluorouracil resistance in human pancreatic cancer cells by
regulating PTEN and PDCD4. Cancer Med. 5:693–702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neoptolemos JP, Dunn JA, Stocken DD,
Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P,
Dervenis C, et al: Adjuvant chemoradiotherapy and chemotherapy in
resectable pancreatic cancer: A randomised controlled trial.
Lancet. 358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Laethem JL, Hammel P, Mornex F, Azria
D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer
M, et al: Adjuvant gemcitabine alone versus gemcitabine-based
chemoradiotherapy after curative resection for pancreatic cancer: A
randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J
Clin Oncol. 28:4450–4456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: A phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sutton JM and Abbott DE: Neoadjuvant
therapy for pancreas cancer: Past lessons and future therapies.
World J Gastroenterol. 20:15564–15579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miglietta A, Toselli M, Ravarino N, Vencia
W, Chiecchio A, Bozzo F, Motta M, Torchio B and Bocca C: COX-2
expression in human breast carcinomas: Correlation with
clinicopathological features and prognostic molecular markers.
Expert Opin Ther Targets. 14:655–664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Richardsen E, Uglehus RD, Due J, Busch C
and Busund LT: COX-2 is overexpressed in primary prostate cancer
with metastatic potential and may predict survival. A comparison
study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol.
34:316–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang J, Xue M, Yang S, Yao B, Zhang B,
Chen X, Pozzi A and Zhang MZ: Inhibition of 11β-Hydroxysteroid
Dehydrogenase type II suppresses lung carcinogenesis by blocking
tumor COX-2 expression as well as the ERK and mTOR signaling
pathways. PLoS One. 10:e01270302015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jakstaite A, Maziukiene A, Silkuniene G,
Kmieliute K, Gulbinas A and Dambrauskas Z: HuR mediated
post-transcriptional regulation as a new potential adjuvant
therapeutic target in chemotherapy for pancreatic cancer. World J
Gastroenterol. 21:13004–13019. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Gu Z, Xiao Z, Zhou T, Li J and Sun
K: Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor
through matrix metalloproteinase 14 pathway in PANC-1 cells. Int J
Clin Exp Pathol. 8:1737–1742. 2015.PubMed/NCBI
|
|
16
|
Eibl G, Reber HA, Wente MN and Hines OJ:
The selective cyclooxygenase-2 inhibitor nimesulide induces
apoptosis in pancreatic cancer cells independent of COX-2.
Pancreas. 26:33–41. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Funahashi H, Satake M, Dawson D, Huynh NA,
Reber HA, Hines OJ and Eibl G: Delayed progression of pancreatic
intraepithelial neoplasia in a conditional Kras(G12D) mouse model
by a selective cyclooxygenase-2 inhibitor. Cancer Res.
67:7068–7071. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eibl G, Takata Y, Boros LG, Liu J, Okada
Y, Reber HA and Hines OJ: Growth stimulation of COX-2-negative
pancreatic cancer by a selective COX-2 inhibitor. Cancer Res.
65:982–990. 2005.PubMed/NCBI
|
|
19
|
Kishimoto H, Hamada K, Saunders M, Backman
S, Sasaki T, Nakano T, Mak TW and Suzuki A: Physiological functions
of Pten in mouse tissues. Cell Struct Funct. 28:11–21. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J,
Zhu G, Wang X, Chang LS, He D and Li L: Kaempferol suppresses
bladder cancer tumor growth by inhibiting cell proliferation and
inducing apoptosis. Mol Carcinog. 54:831–840. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu JR, Wu WJ, Liu SX, Zuo LF, Wang Y,
Yang JZ and Nan YM: Nimesulide inhibits the growth of human
esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway.
Pathol Res Pract. 211:426–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Neoptolemos JP, Stocken DD, Bassi C,
Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger
S, Mariette C, et al: Adjuvant chemotherapy with fluorouracil plus
folinic acid vs gemcitabine following pancreatic cancer resection:
A randomized controlled trial. JAMA. 304:1073–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su M, Mei Y and Sinha S: Role of the
crosstalk between autophagy and apoptosis in cancer. J Oncol.
2013:1027352013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Satoh K, Kaneko K, Hirota M, Masamune A,
Satoh A and Shimosegawa T: Expression of survivin is correlated
with cancer cell apoptosis and is involved in the development of
human pancreatic duct cell tumors. Cancer. 92:271–278. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan Z, Chen D, Chen X and Wei Y: Novel
combination of Vincristine and COX-2 Inhibitor Nimesulide provides
synergistic anti-proliferative and pro-apoptotic effects in KOSC-2
oral squamous carcinoma cells. Int J Clin Exp Me. 9:877–887.
2016.
|
|
27
|
Kumar S, Eroglu E, Rd SJ, Stokes JA III,
Scissum-Gunn K, Saldanha SN, Singh UP, Manne U, Ponnazhagan S and
Mishra MK: Resveratrol induces mitochondria-mediated,
caspase-independent apoptosis in murine prostate cancer cells.
Oncotarget. 8:20895–20908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhola PD and Letai A: Mitochondria-judges
and executioners of cell death sentences. Mol Cell. 61:695–704.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma J, Sawai H, Ochi N, Matsuo Y, Xu D,
Yasuda A, Takahashi H, Wakasugi T and Takeyama H: PTEN regulates
angiogenesis through PI3K/Akt/VEGF signaling pathway in human
pancreatic cancer cells. Mol Cell Biochem. 331:161–171. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ying H, Elpek KG, Vinjamoori A, Zimmerman
SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W,
et al: PTEN is a major tumor suppressor in pancreatic ductal
adenocarcinoma and regulates an NF-κB-cytokine network. Cancer
Discov. 1:158–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cheng TC, Lai CS, Chung MC, Kalyanam N,
Majeed M, Ho CT, Ho YS and Pan MH: Potent anti-cancer effect of
3′-hydroxypterostilbene in human colon xenograft tumors. PLoS One.
9:e1118142014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gowda R, Madhunapantula SV, Desai D, Amin
S and Robertson GP: Simultaneous targeting of COX-2 and AKT using
selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther. 12:3–15.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hodgson MC, Deryugina EI, Suarez E, Lopez
SM, Lin D, Xue H, Gorlov IP, Wang Y and Agoulnik IU: INPP4B
suppresses prostate cancer cell invasion. Cell Commun Signal.
12:612014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Farrow B and Evers BM: Activation of
PPARgamma increases PTEN expression in pancreatic cancer cells.
Biochem Biophys Res Commun. 301:50–53. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang D, Chang JR, Chin AJ, Smith A, Kelly
C, Weinberg ES and Ge R: The role of vascular endothelial growth
factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in
zebrafish development. Mech Dev. 108:29–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wen S, Stolarov J, Myers MP, Su JD, Wigler
MH, Tonks NK and Durden DL: PTEN controls tumor-induced
angiogenesis. Proc Natl Acad Sci USA. 98:4622–4627. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
An X, Lv H, Tian J, He X and Ling N: Role
of the PTEN/PI3K/VEGF pathway in the development of Kawasaki
disease. Exp Ther Med. 11:1318–1322. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carracedo A and Pandolfi PP: The PTEN-PI3K
pathway: Of feedbacks and cross-talks. Oncogene. 27:5527–5541.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Song Z, Bhagat G, Quante M, Baik GH,
Marrache F, Tu SP, Zhao CM, Chen D, Dannenberg AJ and Wang TC:
Potential carcinogenic effects of cigarette smoke and Swedish moist
snuff on pancreas: A study using a transgenic mouse model of
chronic pancreatitis. Lab Invest. 90:426–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Juuti A, Louhimo J, Nordling S, Ristimäki
A and Haglund C: Cyclooxygenase-2 expression correlates with poor
prognosis in pancreatic cancer. J Clin Pathol. 59:382–386. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ristimäki A, Sivula A, Lundin J, Lundin M,
Salminen T, Haglund C, Joensuu H and Isola J: Prognostic
significance of elevated cyclooxygenase-2 expression in breast
cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
43
|
Li CJ, Chang JK, Wang GJ and Ho ML:
Constitutively expressed COX-2 in osteoblasts positively regulates
Akt signal transduction via suppression of PTEN activity. Bone.
48:286–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vo BT, Morton D Jr, Komaragiri S, Millena
AC, Leath C and Khan SA: TGF-β effects on prostate cancer cell
migration and invasion are mediated by PGE2 through activation of
PI3K/AKT/mTOR pathway. Endocrinology. 154:1768–1779. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Subbaramaiah K, Norton L, Gerald W and
Dannenberg AJ: Cyclooxygenase-2 is overexpressed in
HER-2/neu-positive breast cancer: Evidence for involvement of AP-1
and PEA3. J Biol Chem. 277:18649–18657. 2002. View Article : Google Scholar : PubMed/NCBI
|
